Oxford Kovid vaccine attracts immune response in older young people: AstraZeneca

AstraZeneca is at the forefront of vaccine production (dossier)


One of the world’s leading experimental COVID-19 vaccines is producing an immune response in young and old adults, raising hopes of a way out of the depressing and economic devastation generated by the new coronovirus.

The vaccine, developed by the University of Oxford, also causes fewer side effects in the elderly, British drug maker AstraZeneca plc, which helps manufacture the vaccine, said on Monday.

A vaccine that is seen as a game changer in the fight against the novel coronavirus that has killed over 1.15 million people, blocking part of the global economy and reversing the normal lives of billions of people.

A spokesperson for AstraZeneca said: “It is encouraging to see that the immunological responses were similar between older and younger adults and lower reactivity, where the severity of the COVID-19 disease is higher.”

“The results further form the body of evidence for the safety and immunity of AZD1222,” the spokesperson said, citing the technical name of the vaccine.

The Oxford / AstraZeneca vaccine is one of the biggest safe drugs with Pfizer and BioNotech, a candidate for regulatory approval as the world tries to emerge from the COVID-19 pandemic.

The news that older people have an immune response to the vaccine is positive as the immune system weakens with age and older people are most at risk of dying from the virus. If that works, a vaccine will allow the world to take certain actions. Normality after epidural tumors.

British Health Secretary Matt Hancock said a vaccine was not yet ready but was preparing logistics for a possible deployment in the first half of 2021.

When asked if there are people who can get vaccinated this year, he told the BBC: “I’m not ruling it out, but it’s not my centralization.”

“The program is progressing well, (but) we are not there yet,” Hancock said.

Work on the Oxford vaccine began in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral vector vaccine is made up of a weaker version of a common cold virus that causes infection in chimpanzees.

The chimpanzee cold virus has been genetically modified to include a genetic sequence of so-called spike proteins that coronoviruses use to enter human cells. The hope is that the human body will attack the new coronovirus again if it sees it again.

The Financial Times previously reported that the vaccine generated from the “chronic immune response” in a group of healthy adults aged 55-18 showed immunization blood tests to be performed on a subset of echo data from older participants released in July.

The FT said details of the discovery are expected to be published soon in a clinical journal. He did not name the post.

Those familiar with the results of so-called immunogenicity blood tests performed on a subset of older participants said the results, released in July, echoed data that “stronger immune responses” occurred in a group of healthy adults between the ages of 18 and 55. .

AstraZeneca has signed a number of supply and manufacturing agreements with companies and governments around the world as it is close to releasing the first results of an advanced stage clinical trial.

It has resumed US testing of the experimental vaccine after approval from US regulators, the company said on Friday.

The Sun newspaper reported on Monday that staff at a London hospital had been told they were ready to receive the first batch of the Oxford / AstraZeneca vaccine.

(Except for the title, this story was not edited by NDTV employees and posted from a syndicated feed.)

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: